WSU study finds possible link between childhood obesity and mothers' smoking pre-pregnancy
A study led by Washington State University (WSU) has identified possible links between childhood obesity and whether a mother smoked before pregnancy.
The study found body mass index (BMI) patterns that could predict obesity, with findings published in Jama Network Open.
The research analyzed the BMI trajectories of over 9,400 children, finding that while most children follow a typical BMI development path, 11% showed atypical patterns linked to factors before pregnancy.
'The most distinct finding is that we can identify children on a path to obesity as early as age 3.5 years,' said Chang Liu, an assistant professor of psychology at WSU and the corresponding author of the new paper.
The study used data from the Environmental Influences on Child Health Outcomes (ECHO) program, covering from January 1997 to June 2024.
Children in the atypical BMI group were more likely to have mothers who smoked during pregnancy or had high pre-pregnancy BMI, according to a release from WSU.
The study said these children did not experience the typical BMI decline after their first year and began rapid weight gain by age 3.5, reaching an average BMI above the 99th percentile by age 9.
The study highlights the potential for early intervention, suggesting that identifying at-risk children by age 3.5 could help prevent obesity and its associated health risks.
The findings underscore the importance of early identification and intervention in preventing childhood obesity, with prenatal factors playing a significant role in determining BMI trajectories.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
(Reuters) -AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.
Yahoo
an hour ago
- Yahoo
5 Must-Read Analyst Questions From Astrana Health's Q1 Earnings Call
Astrana Health's first quarter results for 2025 were met with a negative market reaction, with revenue growth driven by its Care Partners segment and progress in full-risk contracts. However, management acknowledged that the quarter's performance was tempered by lower-than-expected revenue and compressed operating margins. CEO Brandon Sim pointed to the flu season and higher emergency room and lab utilization in Medicaid as factors impacting costs, while also highlighting ongoing investments in technology and integration. Sim stated, 'Margins were moderated by planned ongoing investments in growth integration technology, as well as by revenue growth in areas with lower near-term margin profiles.' Is now the time to buy ASTH? Find out in our full research report (it's free). Revenue: $620.4 million vs analyst estimates of $636.2 million (53.4% year-on-year growth, 2.5% miss) Adjusted EPS: $0.34 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $36.39 million vs analyst estimates of $35.7 million (5.9% margin, 1.9% beat) The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint EBITDA guidance for the full year is $180 million at the midpoint, below analyst estimates of $181.2 million Operating Margin: 3.3%, down from 7.5% in the same quarter last year Market Capitalization: $1.23 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ryan Daniels (William Blair) asked about remaining milestones for CHS integration. CEO Brandon Sim explained integration is complete, but further implementation of the care model should drive margin improvements over time. Michael Ha (Baird) pressed on the seasonality and drivers behind the lighter revenue outlook for next quarter. Sim attributed this to Medicaid volatility and full-risk conversions being weighted toward the second half of the year. Jack Slevin (Jefferies) questioned Astrana's confidence in leveraging favorable Medicare Advantage rates. Sim responded that while the rate update was anticipated, its exact financial impact will become clearer as more details emerge. Jailendra Singh (Truist Securities) asked about profitability in the ACO REACH program and the impact of recent risk adjustment changes. Sim shared that the company absorbed a modest drag from retroactive adjustments, offset by other risk-management strategies. Brooks O'Neil (Lake Street Capital Markets) probed on organizational stress from rapid growth and integration. Sim acknowledged the challenges of scaling rapidly, emphasizing ongoing focus on integration and cultural cohesion. In the upcoming quarters, the StockStory team will be monitoring (1) the pace and effectiveness of integrating Prospect Health and realizing promised synergies, (2) the continued conversion of members to full-risk contracts and resulting margin trends, and (3) the outcome of Medicaid contract renewals and regulatory developments in key states. Progress in leadership-driven data and technology initiatives will also be a key signpost for sustainable growth. Astrana Health currently trades at $24.73, down from $33.40 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.


Washington Post
an hour ago
- Washington Post
EPA employees put names to 'declaration of dissent' over agency moves under Trump
A group of Environmental Protection Agency employees on Monday published a declaration of dissent from the agency's policies under the Trump administration, saying they 'undermine the EPA mission of protecting human health and the environment.' More than 170 EPA employees put their names to the document, with about 100 more signing anonymously out of fear of retaliation, according to Jeremy Berg, a former editor-in-chief of Science magazine who is not an EPA employee but was among non-EPA scientists or academics to also sign. The latter figure includes over 70 Nobel laureates.